**Moving Diagnostic Testing Closer to the Patient**

**HemoCue Near Patient Testing Systems Enhance Decision Making, Improve Patient Care**

The HemoCue® Testing Systems offer physicians the convenience and efficiency of lab-quality results at the point of care. With HemoCue test results in hand, the physician or healthcare provider has the opportunity, during a single patient visit, to ask questions, discuss patient lifestyle, review medication history, and begin or adjust medical treatment. HemoCue’s fast, reliable results complement more extensive laboratory test panels that may be required for disease management.

HemoCue’s handheld systems are available for diabetes diagnosis and management and other in-office testing where rapid lab-quality results can lead to more prompt treatment decisions.

**Efficient and effective diabetes management**

Diagnosing and monitoring diabetes is crucial to the health and well-being of millions of people in the U.S. Almost 8% of the U.S. population (23 million) has diabetes, according to the Centers for Disease Control and Prevention (CDC), while another 19% (57 million) are estimated to have pre-diabetes.¹

The HemoCue Glucose System is a near-patient testing system that is FDA-cleared and CLIA-waived for both the diagnosis and management of diabetes.

HemoCue System’s ease of use makes it ideal for glucose measurements in the physician’s office or health care clinic. In addition, the system is not affected by low or high hematocrit or other potential interfering substances and therefore can provide accurate results for neonatal and critical care applications.

**Immediate treatment decisions**

Anemia is diagnosed by measuring hemoglobin. With the HemoCue Hemoglobin System, physicians are able to detect the presence and severity of anemia during a patient’s office visit and begin treatment right away. The FDA-cleared, CLIA-waived system is also useful for monitoring and managing anemia in various settings, including physician offices and dialysis clinics, where it can facilitate appropriate erythropoietin (EPO) dosages.

In hospital settings such as operating rooms and intensive care units, HemoCue provides accurate hemoglobin results in about 60 seconds, allowing doctors to make immediate treatment or surgical decisions.

**Quantitative albumin measurement**

Microalbuminuria – low levels of albumin excreted in the urine – may indicate the presence of chronic kidney disease (CKD) and is a risk marker for cardiovascular disease. With point-of-care albumin testing, physicians can screen in-office and then begin treatment for at-risk patients, such as those with diabetes and hypertension.

Unlike dipstick-based point-of-care urine methods, which indicate if a patient’s microalbumin levels fall within predefined ranges, the HemoCue Albumin 201 System provides the concentration present in the sample within 90 seconds. The system is FDA-cleared and CLIA-waived for screening, diagnosing, and monitoring microalbuminuria.

**Fast white blood cell count measurement**

With the HemoCue WBC System, physicians can get a quantitative determination of a patient’s white blood cell count in about three minutes, while the patient is still in the examination room. The WBC test result along with the patient examination will enable a quicker diagnosis and may help confirm the need for antibiotic treatment.

The HemoCue WBC System is FDA cleared for use in moderate complexity laboratories.

For more information about HemoCue systems, please visit HemoCue.com. HemoCue is a Quest Diagnostics company.

**References:**

Connectivity Options for HemoCue® Systems

The HemoCue Glucose and Hemoglobin systems offer connectivity options that make it easier for health care providers to effectively integrate test results into their own information management systems. Such connectivity can help reduce transcription errors, simplify regulatory compliance, and improve office efficiency.

Secure Options for Physicians

Medical practices have the flexibility of three connectivity options when using HemoCue systems. Patient test results can be securely downloaded to:

1. The HemoCue Data Management System
2. A commercial electronic medical records (EMR) solution via interface to one of the over 250 EMR products available in the U.S.
3. The Care360® Labs & Meds

Once the HemoCue device is placed in the 201 DM docking station, data is automatically transferred to the practice’s PC or centralized server, thereby reducing manual archiving.

Enhanced Connectivity for Urgent Care Facilities

Outpatient urgent care facilities, clinics, or hospitals that have a local area network (LAN) can use one of the existing interfaces to HemoCue Glucose 201 DM or Hemoglobin 201 DM. Interfaces such as those offered by Telcor, MAS-RALS Plus, Sybase, and Laboratory Data Systems provide seamless interfacing, expanded communication capabilities, and rapid access.

HemoCue and the Care360® Labs & Meds

When HemoCue Glucose and Hemoglobin 201 DM analyzers are used with the Care360 Labs & Meds, it is easy to streamline workflow and reduce turnaround time. The Care360 portal provides physicians with 24/7 access to lab and medication records, patient medical history, remote ordering of lab testing and e-prescribing.

Simplified data management. HemoCue 201 DM results can be electronically merged into the Care360 patient record for faster data availability and easier data management.

Enhanced clinical analysis. Physicians can compare HemoCue point-of-care results with prior or subsequent lab test results (e.g., HemoCue Hemoglobin with Quest Diagnostics CBC). Care360 also has the capability to create cumulative trending reports.

Mobile access. Stored HemoCue results can be accessed with mobile devices – including the iPhone® and iPod touch® – from virtually any location, 24/7, with the click of an icon.

For more information about HemoCue system connectivity, visit HemoCue.com. For more about Care360 Labs & Meds, and to watch a Care360 demo, visit QuestDiagnostics.com/hcp/connect.